Novo Nordisk’s phase 3 trials testing semaglutide to slow Alzheimer’s progression failed, causing Copenhagen shares to drop by 6%. The disappointment follows a string of setbacks for Novo, putting pressure on management to focus on other potential revenue streams like the launch of 25 mg oral semaglutide in the US obesity market.

While the trials’ failure was anticipated, Novo’s stock value is maintained at DKK 423 after removing future Alzheimer’s revenue. The company aims to counter market challenges with new launches, projecting roughly $39 billion in total semaglutide sales by 2030. Details of the Alzheimer’s trials will be revealed at the Clinical Trials in Alzheimer’s Disease conference on Dec. 3.

Read more at Morningstar: Novo Nordisk: Alzheimer’s Failure Puts More Pressure on Oral Semaglutide Launch in Obesity